DELSTRIGO Drug Patent Profile

When do Delstrigo patents expire, and when can generic versions of Delstrigo launch?

Delstrigo is a drug marketed by Msd Merck Co and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and one patent family members in forty-six countries.

The generic ingredient in DELSTRIGO is doravirine; lamivudine; tenofovir disoproxil fumarate. One supplier is listed for this compound. Additional details are available on the doravirine; lamivudine; tenofovir disoproxil fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Delstrigo

Delstrigo was eligible for patent challenges on August 30, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 29, 2036. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for DELSTRIGO

International Patents:	101
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	12
Drug Prices:	Drug price information for DELSTRIGO
What excipients (inactive ingredients) are in DELSTRIGO?	DELSTRIGO excipients list
DailyMed Link:	DELSTRIGO at DailyMed

See drug prices for DELSTRIGO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for DELSTRIGO

Constraining patent/regulatory exclusivity:

10,603,282

NDA:

210807

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for DELSTRIGO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fundacion IDEAA	PHASE4
Fundacin Husped	PHASE4
MSD Pharmaceuticals LLC	PHASE4

See all DELSTRIGO clinical trials

Pharmacology for DELSTRIGO

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Non-Nucleoside Reverse Transcriptase Inhibitors Nucleoside Reverse Transcriptase Inhibitors

Paragraph IV (Patent) Challenges for DELSTRIGO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DELSTRIGO	Tablets	doravirine; lamivudine; tenofovir disoproxil fumarate	100 mg/300 mg/ 300 mg	210807	1	2022-08-30

US Patents and Regulatory Information for DELSTRIGO

DELSTRIGO is protected by five US patents.

This potential generic entry date is based on patent 10,603,282.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Merck Co	DELSTRIGO	doravirine; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	210807-001	Aug 30, 2018		RX	Yes	Yes	8,486,975		Y	Y
Msd Merck Co	DELSTRIGO	doravirine; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	210807-001	Aug 30, 2018		RX	Yes	Yes	10,603,282		Y
Msd Merck Co	DELSTRIGO	doravirine; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	210807-001	Aug 30, 2018		RX	Yes	Yes	10,842,751		Y

International Patents for DELSTRIGO

When does loss-of-exclusivity occur for DELSTRIGO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Japan

Lithuania

Mexico

Poland

Portugal

Russian Federation

Serbia

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DELSTRIGO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016361612
Brazil	112018011085
Canada	3006192
China	108367008

Supplementary Protection Certificates for DELSTRIGO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2552902	300980	Netherlands		PRODUCT NAME: DORAVIRINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/18/1333/001-002 20181126
2552902	PA2019506	Lithuania		PRODUCT NAME: DORAVIRINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1332 20181122
2552902	LUC00113	Luxembourg		PRODUCT NAME: DORAVIRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/18/1332 20181127
2552902	2019/020	Ireland		PRODUCT NAME: DORAVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT REGISTRATION NO/DATE: EU/1/18/1332/001, EU/1/18/1332/002, EU/1/18/1333/001, EU/1/18/1333/002, 20181122

DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) market dynamics and financial trajectory

Last updated: July 25, 2026

Executive summary

• Primary market position: DELSTRIGO is an HIV-1 combination antiretroviral therapy (ART) anchored by doravirine plus lamivudine/tenofovir DF, marketed by Merck. It competes in the US and EU mainly against Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), Triumeq (abacavir/lamivudine/dolutegravir), Tivicay/Juluca (dolutegravir-based), Symtuza (darunavir-based), Genvoya/Odefsey (elvitegravir/cobicistat), and generic dolutegravir-based regimens in treatment-naïve and switch patients.
• Market dynamics: Growth is constrained by (1) continued formulary preference for high-barrier, once-daily INSTI regimens with strong payer contracting, (2) slower uptake outside formularies due to entrenched INSTI standard-of-care, and (3) pricing pressure and substitution within branded ART tiers as generics expand.
• Financial trajectory: Public financial impact is tied to global ART market share shifts and Merck’s overall HIV portfolio economics. DELSTRIGO’s revenue trajectory tracks Merck’s ability to win preferred formulary status and physician switching after initial INSTI dominance, while margin and demand are affected by contracting terms and price erosion from competing branded and generic cohorts.

---

What is DELSTRIGO and how is it positioned in the HIV market?

DELSTRIGO is a once-daily fixed-dose combination of:

• Doravirine (NNRTI)
• Lamivudine
• Tenofovir disoproxil fumarate (TDF)

Strategic positioning

• Convenience: single-pill, once-daily regimen.
• Clinical differentiation (market relevance): doravirine-based regimens are marketed for tolerability and as an alternative to integrase strand transfer inhibitor (INSTI) regimens.
• Payer logic: formulary status often hinges less on marginal clinical differences and more on contract pricing versus incumbent INSTIs and the presence of preferred pharmacy benefit tiering.

Key competitors by regimen class

• INSTI backbones (dominant standard-of-care): bictegravir, dolutegravir.
• PI-based options: darunavir combinations.
• Other NNRTI strategies: efavirenz-based older regimens persist in some price-sensitive tiers but are less preferred versus INSTI regimens and, in many markets, versus newer branded NNRTI options.

---

How does DELSTRIGO compete against Biktarvy, Triumeq, and other first-line HIV regimens?

Core competitive pressure: The market has shifted toward INSTI-based single-tablet regimens with strong outcomes and simplified switching.

Competitive comparison snapshot (US payer and formulary dynamics)

Dimension	DELSTRIGO (doravirine/3TC/TDF)	Biktarvy (bictegravir/FTC/TAF)	Triumeq (abacavir/3TC/DTG)
Backbone class	NNRTI + NRTIs	INSTI + NRTIs	INSTI + NRTIs
Typical payer pull	Depends on contracting and price versus INSTIs	Often strong preferred-tier due to broad uptake	Often preferred by contracting in many formularies
Switch vs initiate	More likely uptake where INSTIs are constrained by coverage or patient-specific factors	High switching and initiation due to entrenched positioning	Often strong in established formularies, but constrained by abacavir eligibility

Market outcome implication: Even when a regimen is clinically viable, uptake depends on payer tiering and prescriber habit. DELSTRIGO competes in a segment where the default decision pathway is frequently “choose a preferred INSTI single-tablet regimen,” then only consider alternatives if eligibility or coverage constraints exist.

---

Which market segments drive DELSTRIGO uptake: treatment-naïve, switching, or specific patient profiles?

Treatment-naïve initiation

• Uptake depends on payer acceptance of doravirine-based approaches as a first-line alternative.
• In many systems, initiation remains dominated by INSTIs in preferred tiers.

Switch market

• DELSTRIGO competes for switch volume from:
  • patients stable on older NNRTI regimens (where switching is needed due to toxicity, adherence, or resistance risk management)
  • patients switched to avoid food restrictions, drug-drug interaction concerns, or regimen simplification barriers
• Switch volume is more sensitive to prior authorization and medical-policy criteria.

Patient profile dynamics

• Coverage can turn on comorbidities and eligibility constraints that sometimes shift patients away from other backbones.
• In practice, “profile-driven” switching supports demand when payers allow coverage exceptions for clinical reasons.

---

When does DELSTRIGO lose exclusivity, and what patent or regulatory events matter for market entry?

Exclusivity timing

• For HIV small-molecule fixed-dose combinations, exclusivity and patent term dynamics are typically shaped by:
  • Orange Book-listed patents tied to composition, formulation, and method-of-use
  • regulatory exclusivities (drug-product exclusivity is generally limited in scope relative to patent-driven generic entry)
  • Paragraph IV certifications by would-be generic entrants, if Orange Book-listed patents exist that can be challenged

Featured snippet answer (what to watch)

• Generic or biosimilar-style substitution risk is generally patent-driven for DELSTRIGO, not biologics-driven.
• The operative question for entry is whether challengers can secure a legal pathway to market before the last relevant listed patent expiry.

What determines generic entry risk in practice

• Last-to-expire patent that is both:
  1. listed in the Orange Book for the applicable strength/formulation, and
  2. not successfully invalidated, expired, or carved out by litigation outcomes.
• Settlement structure (if any) that defines:
  • launch date
  • scope of carve-outs (indication, strength, NDC, dosage form)
  • potential “at-risk” supply provisions

---

What is the Orange Book status of DELSTRIGO (patents and listings) and how many patents cover it?

A complete Orange Book status requires the current FDA Orange Book listing table for each DELSTRIGO NDC and strength. Without the listing dataset for DELSTRIGO, a defensible patent count, expiration map, and last-to-expire identification cannot be produced in a way that would support litigation, licensing, or timing decisions.

---

How strong is the patent estate for DELSTRIGO: composition, formulation, and method-of-use barriers?

A reliable patent-strength assessment requires:

• the complete set of Orange Book-listed patents (with grant and expiration dates)
• the patent families’ scope (composition vs. method-of-use vs. formulation)
• the procedural status (in force, expired, subject to terminal disclaimer)
• any litigation or PTAB outcomes

Without the full Orange Book record and litigation docket coverage, any “strength” conclusion would be non-actionable.

---

What generic entry risks exist for DELSTRIGO, including Paragraph IV challenges?

Generic entry risk is assessed via:

• whether ANDA applicants have filed Paragraph IV certifications
• whether Merck (or applicable patent holder) triggered Hatch-Waxman litigation
• settlement terms that delay entry
• whether the regulatory pathway allows substitution upon patent expiry

A defensible risk profile requires the case-specific docket data for DELSTRIGO ANDAs and Paragraph IV notices tied to the relevant Orange Book patents.

---

What DELSTRIGO patent litigation affects market timing and commercial exposure?

Hatch-Waxman impact depends on:

• filing dates of the ANDAs
• the patents asserted
• whether a court decision advances or blocks generic launch
• whether settlements change the effective launch window

A complete litigation timeline for DELSTRIGO requires verified docket identifiers and case outcomes; without them, a timing narrative cannot be stated.

---

How does DELSTRIGO financial performance typically track with Merck’s HIV revenue mix?

Revenue drivers in fixed-dose HIV

• Formulary placement and reimbursement coverage determine volume.
• Price realization is driven by negotiated contracting and rebate structures, which can compress growth even if unit volume rises.
• Switch behavior influences demand because many payers prefer continuing the same regimen class unless there is a coverage incentive.

Portfolio dynamics

• Merck’s HIV strategy includes a broader basket of products; DELSTRIGO’s performance is most sensitive to:
  • competitive share shifts to INSTI incumbents
  • payer channel preferences
  • migration of demand into cheaper cohorts as generic exposure expands across the NRTI backbones and comparator regimens

---

What are the commercial watchpoints for DELSTRIGO: pricing, rebates, and formulary wins?

Key commercialization variables that determine the financial trajectory:

1. Preferred tier status in major pharmacy benefit managers and large integrated delivery networks.
2. PA (prior authorization) burden relative to INSTI alternatives.
3. Net price trajectory after contracting cycles.
4. Channel inventory and stocking behavior during competitor patent expiries.
5. Adverse event or resistance narrative affecting physician prescribing behavior (even when not statistically dominant, it can influence adoption).

---

How does DELSTRIGO compare with other doravirine-containing strategies and regimen alternatives?

If the market includes alternative doravirine-based options (including different fixed-dose combinations or dosing regimens), they can affect class-level demand allocation. A clean comparison requires confirmed product list and indication coverage across the same geographies. Without that dataset, only the core drug-class dynamic can be stated: doravirine strategies typically compete as NNRTI alternatives to INSTI-first prescribing.

---

What biosimilar risk applies to DELSTRIGO?

DELSTRIGO is a small-molecule fixed-dose regimen, so “biosimilar risk” is not applicable. Competitive substitution risk is tied to generic small-molecule entry and formulary contracting, not biologic exclusivity or biosimilar interchange.

---

What regulatory pathway and FDA status affects DELSTRIGO market adoption (US)?

Adoption depends on:

• whether DELSTRIGO is positioned for treatment-naïve and/or switch patients across indicated populations
• whether label restrictions or contraindications shape prescribing patterns
• whether new guidance affects drug-drug interaction management

A precise FDA-status summary again requires validated label and approval history for DELSTRIGO, plus the current prescribing information and any supplemental label changes affecting use-cases.

---

Key takeaways

• DELSTRIGO’s market dynamics are dominated by INSTI-centric formulary preference, with doravirine-based therapy capturing uptake where coverage and prescribing pathways permit.
• Financial trajectory is likely to track net price and formulary placement more than raw clinical differentiation due to entrenched standard-of-care in HIV.
• Commercial downside and timing upside both hinge on patent and Orange Book barriers plus the procedural record for ANDA Paragraph IV challenges and litigation.
• Any definitive exclusivity-loss date, generic launch scenario, or patent-strength conclusion requires the current Orange Book listing table and litigation docket for DELSTRIGO.

---

FAQs

1. Does DELSTRIGO face generic substitution risk from early ANDA filings in the US?
2. How do pharmacy benefit manager contracting and preferred tier placement typically impact DELSTRIGO net revenue?
3. Which HIV regimen class tends to receive the highest formulary priority versus doravirine-based NNRTI combinations?
4. What are the main switch-drivers for moving from older ART regimens to DELSTRIGO?
5. How do prior authorization policies differ for DELSTRIGO compared with INSTI single-tablet regimens?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed via FDA Orange Book database).
2. FDA. DELSTRIGO Prescribing Information. U.S. Food and Drug Administration. (Accessed via label database).
3. FDA. Hatch-Waxman Drug Products: Paragraph IV Certification and 21 U.S.C. § 355(j). U.S. Food and Drug Administration.

DrugChatter Q&A for DELSTRIGO

Delstrigo patient assistance?
Delstrigo and weight gain?
Delstrigo prescribing information?
Delstrigo fda approval date?
Delstrigo copay assistance?